DOCSLIB.ORG

Who-Hq-Organigram.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Who-Hq-Organigram.Pdf World Health Organization Headquarters* (as of 10 May 2021) Director-General (1) Dr Tedros Adhanom *Click on the Division for further details GHEBREYESUS WHO Office at the Chef de Cabinet (1) Dr Catharina BOEHME United Nations Mr Stewart SIMONSON Envoy for Multilateral Affairs Dr Agnès BUZYN Deputy Director-General (2) Health Emergencies Dr Zsuzsanna JAKAB Preparedness and Response Dr Michael RYAN External Relations and Business Operations Data, Analytics and Chief Scientist UHC/Life Course UHC/Communicable and UHC/Healthier Antimicrobial Resistance Access to Medicines and Emergency Response Emergency Preparedness 4 Governance Mr Raul THOMAS Delivery for Impact and Science Division Dr Zsuzsanna JAKAB (a.i.) Noncommunicable Populations Dr Hanan BALKHY Health Products Dr Soce FALL Dr Jaouad MAHJOUR Ms Jane ELLISON Dr Samira ASMA Dr Soumya SWAMINATHAN Diseases Dr Ren MINGHUI Dr Naoko YAMAMOTO Dr Mariangela SIMÃO Planning,Resource Quality Assurance of Special Programme on Global Malaria Environment, Climate Surveillance, Health Product Policy Health Emergency Health Security Governing Bodies Coordinationand Data and Analytics PerformanceMonitoring Norms and Standards Primary Health Care Programme Change and Health Prevention and Control and Standards Interventions Preparedness Digital Health and Control of Neglected Social Determinants Global Coordination Regulation and Health Emergency Resource Mobilization Finance Health Workforce Global Infectious Innovation Tropical Diseases of Health and Partnership Prequalification Informationand Risk Assessment Hazard Preparedness Delivery for impact Health and Multilateral Human Resources and Integrated Health Global HIV, Hepatitis Nutrition and Food Strategic Health Country Readiness Partnerships Research for Health Talent Management Services and STIs Programmes Safety Operations Strengthening TDR, the Special Programme Staff Health and Health Systems Global Tuberculosis Wellbeing for Research and Training in Governanceand Financing Health Promotion Tropical Diseases Programme InformationManagement Alliancefor Health Policy Immunization,Vaccines Noncommunicable WHO Centre for Health and Technology and Systems Research and Biologicals Diseases Development (Kobe) Sexual and Reproductive Mental Health and Global Service Centre Health and Research (includingHRP)5 Substance Use Maternal,Newborn, Child Operational Support and AdolescentHealth, and Services and Ageing Partnershipfor Maternal, Procurement and Newborn and Child Supply Services Health Security Services (1) Includes: Office of the Director General, Polio Eradication (POL), Communication (DCO); Office of Internal Oversight Services (IOS), Evaluation Unit (EVL), Office of the Legal Counsel (LEG), Compliance and Risk Management and Ethics (CRE), Office of the Ombudsman and Mediation Services (OMB), Country Strategy and Support (CSS), Transformation Implementation and Change (TIC); (2) Includes: DDG Office, Chief Nurse, Global NCD Platform, Health and Migration Co-sponsored Programme, Hosted Partnership or Other Hosted Entity Antimicrobial Resistance Dr Hanan BALKHY ([email protected] ) Full Name Department eMail VAN WEEZENBEEK, Doctor Catharina Simonne Beatrix HQ/SPC Surveillance, Prevention and Control [email protected] GETAHUN GEBRE, Doctor Haileyesus HQ/GCP Global Coordination and Partnership [email protected] Business Operations Mr Raul THOMAS ( [email protected] ) Full Name Department eMail HOLLO, Mr Imre HQ/PRP Planning Resource Coordination and Per Monitoring [email protected] KYRIACOU, Mr George HQ/FNM Finance (Comptroller) [email protected] LINKINS, Ms Jennifer Marie HQ/HRT Human Resources and Talent Management [email protected] CROSS, Doctor Caroline Marie HQ/SHW Staff Health and Wellbeing [email protected] JUNIOR, Mr Bernardo Mariano Joaquim HQ/IMT Information Management and Technology [email protected] PRINGLE, Mr Angus (a.i.) HQ/GSC Global Service Centre [email protected] EL-KHODARY, Mr Hatem HQ/OSS Operational Support and Services [email protected] KASTNER, Ms Angela HQ/SUP Procurement and Supply Services [email protected] under recruitment HQ/SEC Security Services Deputy Director-General Dr Zsuzsanna JAKAB ([email protected] ) Full Name Department eMail SHEIKH, Doctor Mubashar Riaz HQ/DDO Office of the Deputy Director-General [email protected] IRO, Ms Elizabeth HQ/CNO Chief Nurse [email protected] AKSELROD, Doctor Svetlana Valeryevna HQ/GNP Global NCD Platform [email protected] SEVERONI, Mr Santino HQ/PHM Health and Migration Programme [email protected] Data, Analytics and Delivery for Impact Dr Samira ASMA ([email protected] ) Full Name Department eMail CHATTERJI, Doctor Somnath (a.i.) HQ/DNA Data and Analytics [email protected] URSU, Doctor Pavel HQ/DFI Delivery for Impact [email protected] Director-General’s Office Dr Tedros Adhanom GHEBREYESUS ([email protected] ) Dr Catharina BOEHME ([email protected] ) Director General's OfficeSenior Leadership Full Name Assistants Director-General eMail BUZYN, Doctor Agnès HQ/EMA Envoy for Multilateral Affairs [email protected] SIMONSON, Mr Stewart HQ/WUN WHO Office at the United Nations [email protected] GUERRA, Doctor Raniero Senior Adviser - Director General's Office [email protected] SCHWARTLANDER, Doctor Bernhard Senior Strategic Adviser - Director General's Office [email protected] SIMELELA, Doctor Princess Nothemba Assistant Director General - Director General's Office [email protected] SINGER, Doctor Peter Alexander Special Adviser - Director General's Office [email protected] Full Name Directors eMail ACHARYA, Doctor Shambhu Prasad HQ/CSS Country Strategy and Support [email protected] AYLWARD, Doctor Raymond Bruce J. HQ/TIC Transformation Implementation and Change [email protected] EL-HALABI, Ms Shenaaz HQ/ODG Office of the Director-General [email protected] MARTINEZ ARAGON, Mr Jose HQ/OMB Office of the Ombudsman and Mediation Services [email protected] MLITZKE, Mr Andreas Horst HQ/CRE Compliance and Risk Management and Ethics [email protected] O' LEARY, Dr Aiden HQ/POL Polio Eradication [email protected] LEVY, Ms Gabriella Stern HQ/DCO Communications [email protected] RENGANATHAN, Doctor Elilarasu HQ/EVL Evaluation Unit [email protected] WALTON, Mr Derek Antony Ruffel HQ/LEG Office of the Legal Counsel [email protected] WEBB, Mr David James HQ/IOS Office of Internal Oversight Services [email protected] Full Name Directors eMail BLANCO MARQUIZO, Doctor Adriana FCTC Head of Convention Secretariat [email protected] SMITH, Doctor Ian Global Preparedness Monitoring Board (GPMB) [email protected] External Relations and Governance Ms Jane ELLISON ([email protected] ) Full Name Department eMail ARMSTRONG, Doctor Timothy Peter HQ/GBS Governing Bodies [email protected] GRAYMORE, Mr John Daniel Carrick Adam HQ/CRM Strategic Engagement [email protected] SILBERSCHMIDT, Doctor Gaudenz Ulrich HQ/HMP Health and Multilateral Partnerships [email protected] UHC/Healthier Populations Dr Naoko YAMAMOTO ([email protected] ) Full Name Department eMail NEIRA, Doctor Maria Purificacion HQ/ECH Environment, Climate Change and Health [email protected] KRUG, Doctor Etienne G.G. HQ/SDH Social Determinants of Health [email protected] BRANCA, Doctor Francesco HQ/NFS Nutrition and Food Safety [email protected] KRECH, Doctor Ruediger HQ/HPR Health Promotion HEP [email protected] BARBER, Doctor Sarah Louise HQ/WKC WHO Centre for Health Development (Kobe) [email protected] Access to Medicines and Health Products Dr Mariangela SIMÂO ([email protected] ) Full Name Department eMail ONDARI, Doctor Clive HQ/HPS Health Product Policy and Standards [email protected] GASPAR, Doctor Rogerio Paulo HQ/RPQ Regulation and Prequalification [email protected] Chief Scientist and Science Division Dr Soumya SWAMINATHAN ([email protected] ) Full Name Department eMail GROVE, Doctor John HQ/QNS Quality Assurance of Norms and Standards [email protected] JUNIOR, Mr Bernardo Mariano Joaquim HQ/DHI Digital Health and Innovation [email protected] REEDER, Professor John Charles HQ/RFH Research for Health [email protected] REEDER, Professor John Charles HQ/TDR Special Programme for TDR [email protected] GHAFFAR, Doctor Abdul HQ/HSR Alliance for Health Policy and Systems Research [email protected] UHC/Communicable and Noncommunicable Diseases Dr Ren MINGHUI ([email protected] ) Full Name Department eMail ALONSO FERNANDEZ, Doctor Pedro Luis HQ/GMP Global Malaria Programme [email protected] MALECELA, Doctor MWELECELE NTULI HQ/NTD Control of Neglected Tropical Diseases [email protected] DOHERTY, Doctor Meg Caroline HQ/HHS Global HIV, Hepatitis and STIs Programmes [email protected] KASAEVA, Doctor Tereza HQ/GTB Global Tuberculosis Programme [email protected] MIKKELSEN, Doctor Bente HQ/NCD Noncommunicable Diseases [email protected] KESTEL, Ms Devora Lillia HQ/MSD Mental Health and Substance Use [email protected] UHC/Life Course Dr Zsuzsanna JAKAB ([email protected] ) Full Name Department eMail DALIL, Doctor Suraya HQ/PHC Special programme on Primary Health Care [email protected] CAMPBELL, Mr James William HQ/HWF Health Workforce [email protected] under recruitment HQ/IHS Integrated Health Services SOUCAT, Doctor Agnès Laure Bernadette HQ/HGF Health Systems Governance and Financing [email protected] O'BRIEN, Doctor Katherine Louise HQ/IVB Immunization, Vaccines and Biologicals [email protected] ASKEW, Doctor Ian David HQ/SRH Sexual and Reproductive Health and Research [email protected] BANERJEE, Doctor Anshu HQ/MCA Maternal, Newborn, Child & Adolescent Health & Ageing [email protected] FOGSTAD, Mrs Helga HQ/NMC Partnership for Maternal Newborn and Child Health [email protected] Health Emergencies Preparedness and
Load more

Recommended publications
  • Download PDF (2.6
    A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low. The benefits of such measures at about $9 trillion far outweigh the costs which are estimated to be around $50 billion—of which $35 billion should be paid by grants from donors and the residual by national governments potentially with the support of concessional financing from bilateral and multilateral agencies. The grant funding gap identified by the Access to COVID-19 Tools (ACT) Accelerator amounts to about $22 billion, which the G20 recognizes as important to address.
    [Show full text]
  • Page 1 May 2021 SD N /2021/4
    May 2021 I M F S T A F F D I S C U S S I O N N O T E A Proposal to End the COVID-19 Pandemic SDN/2021/4 Ruchir Agarwal, Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. A Proposal to End the COVID-19 Pandemic Prepared by Ruchir Agarwal and Gita Gopinath* Authorized for distribution by Gita Gopinath DISCLAIMER: Staff Discussion Notes (SDNs) showcase policy-related analysis and research being developed by IMF staff members and are published to elicit comments and to encourage debate. The views expressed in Staff Discussion Notes are those of the author(s) and do not necessarily represent the views of the IMF, its Executive Board, or IMF management. Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low.
    [Show full text]
  • Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India
    Tuberculosis Diagnostic Research: Beyond the Basics December 13 - 15, 2010, Tuberculosis Research Centre, Chennai, India COURSE SCHEDULE Monday, Dec 13, 2010 Time Lecture Faculty 8.30 AM Welcome and Introductions A Thomas, MS Jawahar, all 9.00 AM The global value chain (blueprint) for TB diagnostics and current M Pai pipeline of diagnostics 9.45 AM New WHO policy on Xpert MTB/RIF CN Paramasivan New WHO policy on serological assays K Steingart 10.30 AM Coffee 10.45 AM Overview of diagnostic research and types of diagnostic study M Pai designs 11.15 AM Landscape of TB diagnostic research M Pai 12.30 PM Lunch 1.30 PM The diagnostic test accuracy design M Pai 2.30 PM Bias in diagnostic research and sources of variation K Steingart 3.30 PM Coffee 4.00 - 5.30 PM Optimism bias in TB diagnostic research & critical appraisal M Pai Tuesday, Dec 14, 2010 Time Lecture Faculty 8.30 AM Setting reference standards in TB diagnostic studies: • Microscopy evaluations CN Paramasivan • Rapid culture methods CN Paramasivan • Molecular assays T Shinnick • Serological assays S Laal • IGRAs and LTBI tests M Pai • Extrapulmonary TB J Peter 10.30 AM Coffee 10.45 PM Lab accreditation and QA in India J Kenneth Ensuring quality in diagnostic trials: • Microscopy studies CN Paramasivan CN Paramasivan • Culture studies T Shinnick • Molecular assay studies S Laal • Immunodiagnostic studies 1 12.00 Noon Introduction to TB biomarker validation S Parida 12.30 PM Lunch 1.30 PM Beyond test accuracy - 1: impact of testing on diagnostic M Pai thinking and clinical decision
    [Show full text]
  • TB Diagnostics in India
    Content and themes This conference will convene industry leaders, innovative thinkers, A 2 researchers, funders, and policy makers, to stimulate increased - industry/biotech engagement in diagnostic innovations that can help TB conferenceday stimulate TB to diagnostics industry/biotech engagementinnovations in in India control in India and elsewhere. Sessions will focus on topics such as market size for TB diagnostics, IVD market analysis and value chain, target product profiles and market needs, frugal innovation and affordable diagnostics, intellectual property issues, regulation of diagnostics, sources of funding, prize models, business models for engaging private sector, scientific obstacles for R&D, barriers to innovation in India, academia-industry relations, and role of emerging economies and BRICS in the next wave of TB innovations. Confirmed speakers & panelists Anu Acharya, Ocimum Biosolutions, Hyderabad, India Tanjore Balganesh, AstraZeneca, Bangalore, India August 25 Steven Buchsbaum, Bill & Melinda Gates Foundation, USA Sanjeev Chaudhry, SRL, India Vir S. Chauhan, ICGEB, New Delhi, India Anand Daniel, Accel Partners, Bangalore, India Dhananjaya Dendukuri, Achira Labs, Bangalore, India TB diagnostics in India - Pradip Desai, Span Diagnostics, Surat, India 2011 26, Bindu Dey, Department of Biotechnology, New Delhi, India From importation and imitation to innovation Puneet Dewan, WHO, SEARO, New Delhi, India August 25 - 26, 2011, Bangalore, India Sami Guzder, Avesthagen, Bangalore, India Hosted by: St. John’s Research Institute,
    [Show full text]
  • Recent Developments in Genomics, Bioinformatics and Drug Discovery to Combat Emerging Drug-Resistant Tuberculosis
    Tuberculosis 101 (2016) 31e40 Contents lists available at ScienceDirect Tuberculosis journal homepage: http://intl.elsevierhealth.com/journals/tube REVIEW Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis * Soumya Swaminathan a, , Jagadish Chandrabose Sundaramurthi b, Alangudi Natarajan Palaniappan c, Sujatha Narayanan d a National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India b Division of Biomedical Informatics, Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India c Department of Clinical Research, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India d Department of Immunology, National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, 600031, India article info summary Article history: Emergence of drug-resistant tuberculosis (DR-TB) is a big challenge in TB control. The delay in diagnosis Received 24 February 2016 of DR-TB leads to its increased transmission, and therefore prevalence. Recent developments in genomics Received in revised form have enabled whole genome sequencing (WGS) of Mycobacterium tuberculosis (M. tuberculosis) from 3- 21 May 2016 day-old liquid culture and directly from uncultured sputa, while new bioinformatics tools facilitate to Accepted 8 August 2016 determine DR mutations rapidly from the resulting sequences. The present drug discovery and devel- opment pipeline is filled with candidate drugs which have shown efficacy against DR-TB. Furthermore, Keywords: some of the FDA-approved drugs are being evaluated for repurposing, and this approach appears Drug-resistant tuberculosis fi Whole genome sequencing promising as several drugs are reported to enhance ef cacy of the standard TB drugs, reduce drug Bioinformatics tolerance, or modulate the host immune response to control the growth of intracellular M.
    [Show full text]
  • Health Technology Assessment Stakeholder's Consultative Workshop 25Thjuly, 2016, India Habitat Centre, New Delhi, India
    Health Technology Assessment Stakeholder’s Consultative Workshop 25thJuly, 2016, India Habitat Centre, New Delhi, India Introduction On the 25th July, 2016, a workshop was jointly convened by the Department of Health research (DHR), Government of India, The Indian Council of Medical Research (ICMR), and the international Decision Support initiative (IDSI) in order to raise awareness of the initiative to institutionalise health technology assessment (HTA) in India. This initiative aims to introduce a more transparent, inclusive, fair, and evidence-based process by which decisions regarding the allocation of health resources are made in India. The official government press release for the event highlighted the interest of the Indian government to utilise the event to learn from international iDSI partners on how HTA can be best utilised to improve access to affordable health care for the people of India towards the ultimate goal of Universal Health Coverage (UHC). The workshop provided the opportunity for key stakeholders within the field to share experiences, and engage in rich discussion and debate regarding the context, need, function, structure, and future plans for this initiative. The conference was well attended with over 200 delegates, including senior members of the Indian government such as the 2 newly appointed ministers of state for health, Shri Faggan Singh Kulaste and Smt Anupriya Patel; The DG of health services, Mr Jagdish Prasad; and the secretary of DHR, Dr Soumya Swaminathan. Speakers at the event included distinguished leaders of health research and public health strategy in India, including Mr Manoj Jhalani, Joint Secretary and Mission Director (NHM), Ministry of Health and Family Welfare, Prof S.
    [Show full text]
  • Looking Forward: Avoiding a Vaccine Cold War” a Recap Featuring World Renown Scientists and Doctors Discussing the Realities of the COVID-19 Pandemic
    All the Best Podcast Episode 48: “Looking Forward: Avoiding a Vaccine Cold War” A recap featuring world renown scientists and doctors discussing the realities of the COVID-19 pandemic Dr. Murphy: The 41st president, George H. W. Bush, was known for many things, but one of which was truly the leader of a team, the assemblage of a team, the inspiration of a team. He had three aspects that he shared with me. He said in crucial things, unity, in important things, diversity and in all things generosity. George: In the first place, I believe that character is a part of being President. Barbara: And life really must have joy. Sam: This is "All the Best." The official podcast of the George and Barbara Bush Foundation. I'm your host, Sam LeBlond, one of their many grandchildren. Here, we celebrate the legacy of these two incredible Americans through friends, family, and the foundation. This is "All the Best." George: I remember something my dad taught me. He said, write your mother, serve your country, and he said, tell the truth. And I've tried to do that in public life. All through it. Barbara: You are a human being first and those human connections with children, with friends are the most important investments you will ever make. George: We stand tonight before a new world of hope and possibilities for our children. A world we could not have contemplated a few years ago. Sam: On behalf of our family and the George and Barbara Bush Foundation. This is "All the Best." ATB Podcast – Vaccine Recap Oct 2020 2 Welcome to "All the Best." I'm your host, Sam LeBlond.
    [Show full text]
  • Kaivan Munshi
    Kaivan Munshi Department of Economics Yale University Hillhouse Avenue 203-432-4479 [email protected] Education Ph.D. Economics Massachusetts Institute of Technology 1995 M.S., M.C.P. University of California, Berkeley 1989 B.Tech. Indian Institute of Technology, Bombay 1986 Honors and Awards 2019 Distinguished Alumnus Award, IIT Bombay 2016 Infosys Prize for the Social Sciences Positions Held 2020 Faculty Research Associate, National Bureau of Economic Research (NBER) 2019 Professor, Department of Economics, Yale University 2018 Associate Member, Toulouse School of Economics 2015-2019 Research Fellow, Centre for Economic Policy Research (CEPR) 2015 Research Fellow, Institute for the Study of Labor (IZA) 2015-2019 Research Fellow, Institute for Fiscal Studies (IFS) 2015-2017 Professorial Fellow, Magdalene College 2014 Research Associate, Harvard-Cambridge Joint Centre for History and Economics 2013-2019 Frank Ramsey Professor of Economics, University of Cambridge 2013 Research Fellow, Centre for Research and Analysis of Migration (CReAM) 2013 Research Associate, Population Research Institute, Pennsylvania State University 2013-2015 Visiting Senior Scholar, Department of Economics, Pennsylvania State University 2011 Associate, Theoretical Research in Development Economics (ThReD) 2010-2016 Co-editor, Journal of Development Economics 2008-2012 Permanent Member, NIH Social Sciences and Population Studies (SSPS) Study Section 2007-2012 Associate Editor, American Economic Review 2007-2008 Associate Editor, Economic Development and Cultural
    [Show full text]
  • 2020 International Cohorts Summit Executive Summary
    MEETING SUMMARY Virtual Summit Zoom May 4-5, 2020 Hosted by the Global Genomic Medicine Collaborative (G2MC) ihccglobal.org Vision for success: TO CREATE A GLOBAL NETWORK FOR TRANSLATIONAL RESEARCH THAT UTILIZES LARGE COHORTS TO ENHANCE THE UNDERSTANDING OF THE BIOLOGICAL AND GENETIC BASIS OF DISEASE AND IMPROVE CLINICAL CARE AND POPULATION HEALTH IHCC Third International Cohorts Virtual Summit Executive Summary In 2015, the National Institutes of Health (NIH) launched an effort to identify all large-scale prospective cohort studies involving at least 100,000 participants to explore the potential of bringing them together to address scientific questions none could answer alone. This effort led to the commission of the Global Genomic Medicine Collaborative (G2MC) to bring together these cohorts through the International HundredK+ Cohort Consortium (IHCC). This group gathered for the First International Cohort Summit in the USA in 2018 followed by a Second Summit in Iceland in 2019. During planning of the Third Summit to take place in Santiago, Chile, the global outbreak of COVID-19 required a transition to virtual meeting format. Approximately 160 attendees from more than 23 countries attended the virtual Summit. The event in Santiago, Chile will be postponed to a date to be determined when attendee health and safety will not be at heightened risk due to COVID-19. The virtual meeting objectives included: To galvanize the IHCC around a visionary charter and path forward (defining the IHCC organization, mission, membership, partnership opportunities, industry engagement). To examine how IHCC can rapidly mobilize worldwide cohorts to address the COVID-19 pandemic. To introduce the IHCC to a Cohort Data Atlas that can be used to stimulate and enable collaborations among cohorts.
    [Show full text]
  • COVID-19 Vaccine Development, Strategy and Implementation
    Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability.
    [Show full text]
  • Virtual Press Conference 27 August 2020
    COVID-19 Virtual Press conference 27 August 2020 Speaker key: MH Margaret Harris TAG Tedros Adhanom Ghebreyesus ST Stephanie MK Dr Maria Van Kerkhove MR Dr Michael Ryan JO Josephine LA Laurent NI Nina BA Dr Bruce Aylward MA Mahab SS Dr Soumya Swaminathan AD Adam TH Theo LA Latika JI Jim BI Bianca 00:00:11 MH Hello, everybody. This is Margareta Harris in WHO headquarters, Geneva welcoming you to our global press conference on COVID-19 today, this Thursday August 27th. We have with us as always in the room the WHO Director-General, Dr Tedros, along with Dr Jaouad Mahjour, our Assistant Director- General for Emergency Preparedness and the International Health Regulations, Dr Maria Van Kerkhove, Technical Lead for COVID-19, Dr Bruce Aylward, Senior Advisor to the Director- General, who leads on the ACT Accelerator, and Devora Kestel, Director of our Mental Health and Substance Use department. Dr Mariangela Simao will join us later and we're also being joined remotely by Dr Mike Ryan, Executive Director of our Emergencies Programme, and Dr Soumya Swaminathan, our Chief Scientist. As usual we are translating this simultaneously into the six official UN languages plus Portuguese and Hindi and we'll be posting the Director-General's remarks and an audio file of the press conference on the web as soon as possible. Transcripts will also be available later. Now without further delay I will hand over to Dr Tedros to give his opening remarks. Dr Tedros, you have the floor. TAG Thank you. Thank you, Margareta. Good morning, good afternoon and good evening.
    [Show full text]
  • HZS C2BRNE DIARY – January 2021
    1 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 2 HZS C2BRNE DIARY – January 2021 HZS C2BRNE DIARY– 2021© January 2021 Website: www.cbrne-terrorism-newsletter.com Editor-in-Chief BrigGEN (ret.) Ioannis Galatas MD, MSc, MC (Army) PhD cand Consultant in Allergy & Clinical Immunology Medical/Hospital CBRNE Planner & Instructor Senior Asymmetric Threats Analyst Manager, CBRN Knowledge Center @ International CBRNE Institute (BE) Senior CBRN Consultant @ HotZone Solutions Group (NL) Athens, Greece Contact e-mail: [email protected] Editorial Team ⚫ Bellanca Giada, MD, MSc (Italy) ⚫ Hopmeier Michael, BSc/MSc MechEngin (USA) ⚫ Kiourktsoglou George, BSc, Dipl, MSc, MBA, PhD (UK) ⚫ Photiou Steve, MD, MSc EmDisaster (Italy) ⚫ Tarlow Peter, PhD Sociol (USA) A publication of HotZone Solutions Group Prinsessegracht 6, 2514 AN, The Hague, The Netherlands T: +31 70 262 97 04, F: +31 (0) 87 784 68 26 E-mail: [email protected] DISCLAIMER: The HZS C2BRNE DIARY® (former CBRNE-Terrorism Newsletter), is a free online publication for the fellow civilian/military CBRNE First Responders worldwide. The Diary is a collection of papers/articles related to the stated thematology. Relevant sources/authors are included and all info provided herein is from open Internet sources. Opinions and comments from the Editor, the Editorial Team or the authors publishing in the Diary do not necessarily represent those of the HotZone Solutions Group (NL) or the International CBRNE Institute (BE). www.cbrne-terrorism-newsletter.com 3 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 4 HZS C2BRNE DIARY – January 2021 www.cbrne-terrorism-newsletter.com 5 HZS C2BRNE DIARY – January 2021 Editorial Brig Gen (ret.) Ioannis Galatas, MD, MSc, MC (Army) Editor-in-Chief HZS C2BRNE Diary Dear Colleagues, New Year, Blank Page? effects and duration of effectiveness of vaccination.
    [Show full text]